16 Jun 2026
Zydus Lifesciences completed its acquisition of US-listed Assertio Holdings through a 23.50 dollar per share cash tender, taking the company private and delisting it from Nasdaq.
The deal hands Zydus an established US specialty oncology platform anchored by ROLVEDON, used to prevent febrile neutropenia in cancer patients. About 66 percent of Assertio shares were tendered before the merger closed.